Stay updated with breaking news from Cell Host. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Researchers at NYU Grossman School of Medicine and Janssen Biotech, Inc. have shown in early tests that a bioengineered drug candidate can counter infection with Staphylococcus aureus – a bacterial species widely resistant to antibiotics and a major cause of death in hospitalized patients.
Ever since chronic fatigue syndrome — or myalgic encephalomyelitis — was identified in the 1980s, its cause has been a mystery.
Researchers explored commensalism and pathogenesis relationships in the human mycobiome.
The researchers provide important insights into the cross-feeding mechanisms of nutrients in the gut microbiome and their impacts on host health.
MIT researchers find Staphylococcus aureus can rapidly evolve within a single person’s microbiome. In people with eczema, S. aureus tends to evolve to a variant with a mutation in a specific gene that helps it grow faster on the skin.